HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Idarucizumab: First Global Approval.

Abstract
Idarucizumab (Praxbind(®)) is a fully humanized, monoclonal antibody fragment developed by Boehringer Ingelheim as a specific antidote to reverse the anticoagulant effect of the direct oral thrombin inhibitor dabigatran etexilate (Pradaxa(®)). Idarucizumab received its first global approval, in the USA, in October 2015 for use in adult patients treated with dabigatran etexilate when rapid reversal of its anticoagulant effects is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding. Regulatory applications have been submitted in Canada and in the EU, where it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use. This article summarizes the milestones in the development of idarucizumab leading to this first approval for reversing the anticoagulant effects of dabigatran in adults.
AuthorsCeleste B Burness
JournalDrugs (Drugs) Vol. 75 Issue 18 Pg. 2155-61 (Dec 2015) ISSN: 1179-1950 [Electronic] New Zealand
PMID26578027 (Publication Type: Journal Article, Review)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Antidotes
  • Antithrombins
  • idarucizumab
  • Dabigatran
Topics
  • Adult
  • Antibodies, Monoclonal, Humanized (pharmacology, therapeutic use)
  • Antidotes (pharmacology, therapeutic use)
  • Antithrombins (adverse effects)
  • Blood Coagulation (drug effects)
  • Dabigatran (adverse effects)
  • Drug Approval
  • Hemorrhage (chemically induced, drug therapy)
  • Humans

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: